Goldstein Joseph L's Form 4 filing
Regeneron Pharmaceuticals, Inc. (REGN) · filed Jan 25, 2024
- Accession no.
- 0001968202-24-000042
- Filed
- Jan 25, 2024
- Trade date
- Jan 23, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $2.57M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Goldstein Joseph LCIK 0001225474 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 23, 2024 | Common Stock | MOption exerciseAcquired | +2,707 | $625.60 | +$1,693,499.2 | 9,089 | Direct | |
| Jan 23, 2024 | Common Stock | SSaleDisposed | −2,707 | $950.00 | −$2,571,650 | 6,382 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 23, 2024 | Common Stock | MOption exerciseDisposed | −2,707 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.